Your session is about to expire
← Back to Search
Immunotherapy + Chemotherapy for Lung Cancer (CheckMate 816 Trial)
CheckMate 816 Trial Summary
This trial is testing a new way to treat lung cancer that may be more effective and have fewer side effects than the current standard of care.
CheckMate 816 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCheckMate 816 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533CheckMate 816 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My lungs are strong enough for surgery.I am fully active or can carry out light work.I have a sample of my lung tumor available.I am fully active or can carry out light work.I have been treated with drugs that boost the immune system.You have a known autoimmune disease that is currently active or suspected.My lungs are strong enough for surgery.My lung cancer is in early stage IB-IIIA and can be operated on.My lung cancer is at an early stage (IB-IIIA) and can be operated on.My cancer cannot be removed by surgery and may have spread.
- Group 1: Platinum doublet chemotherapy
- Group 2: Nivolumab plus platinum doublet chemotherapy
- Group 3: Nivolumab plus Ipilimumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other clinical research has been conducted using Nivolumab?
"Nivolumab was first studied in 1997 at City of Hope Comprehensive Cancer Center. 3741 studies have been completed to date, with 2661 more presently underway - a large number of which are based out of Montreal, Quebec."
What are the most popular conditions that Nivolumab is used to treat?
"Nivolumab is frequently used as an initial treatment, but it can also be useful for patients with metastatic bladder cancer, small cell lung cancer (sclc), or advanced testicular cancer."
Is this clinical trial limited to a single province in Canada?
"This trial is currently recruiting 100 patients from a total of 103 locations, with Local Institution - 0138 in Montreal, Local Institution - 0017 in High Point, and Local Institution - 0140 in Salt Lake City being just some of the participating sites."
When was Nivolumab cleared by the FDA?
"Nivolumab's safety was rated a 3 by our team at Power. This is because Phase 3 trials have both efficacy and multiple rounds of data supporting safety."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger